Development of a new vesicular formulation for delivery of Ifosfamide: Evidence from in vitro, in vivo, and in silico experiments

Hajinezhad, Mohammad Reza; Shahraki, Somaye; Nikfarjam, Zahra; Davodabadi, Fatemeh; Mirinejad, Shekoufeh; Rahdar, Abbas; Sargazi, Saman; Barani, Mahmood

doi:10.1016/j.arabjc.2023.105086

Cited by 11 publications

(3 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hajinezhad and et al designed a novel encapsulate ifosfamide (IFO) niosomal nanometric size range with a high drug-loading capacity and evaluate the anticancer effectiveness of the encapsulate IFO. They result showed that niosomal IFO had desirable anticancer activity against breast cancer (MCF7) and neuroblastoma (SH-SY5Y) cells with a high potential in the controlled release of IFO [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell

Firouzi Amandi,

Bahmanyar,

Dadashpour

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Recently, the presence of different nanoparticles (NPs) has developed targeting drug delivery in treatment of cancer cell. Targeted drug delivery systems using NPs have shown great promise in improving the efficacy of intracellular uptake as well as local concentration of therapeutics with minimizing side effects. The current study planned to synthesized resveratrol-loaded magnetic niosomes nanoparticles (RSV-MNIONPs) and evaluate their cytotoxicity activity in pancreatic cancer cells. For this aim, magnetic nanoparticles (MNPs) were synthesized and loaded into niosomes (NIOs) by the thin film hydration technique and then characterized via DLS, FT-IR, TEM, SEM and VSM techniques. Moreover, the cytotoxic activity of the RSV-MNIONPs on the Capan-1 cells line was assessed by the MTT test. The distribution number of RSV-MNIONPs was gained about 80 nm and 95 nm with surface charge of − 14.0 mV by SEM and TEM analysis, respectively. RSV loading efficacy in NIOs was about 85%, and the drug releases pattern displayed a sustained discharge with a maximum amount about 35% and 40%, within 4 h in pH = 7.4 and pH = 5.8, respectively. The cytotoxicity of the RSV-MNIONPs in the presence of an external magnetic field is higher than that of the RSV, indicating enhanced cellular uptake in their encapsulated states. Furthermore, RSV loaded MNNPs were found to induce more cell cycle arrest at the G0/G1 checkpoint than free RSV. Compared with RSV-treated cells, the mRNA expression levels of BAX, Bcl2, FAS, P 53, Cyclin D and hTERT, were significantly changed in cells treated with RSV loaded MNNPs. The niosomes NPs approaches have been widely used to attain higher solubility, improved bioavailability, enhanced stability, and control delivery of RSV. Our formulation displayed antitumor activity and can be considered an appropriate carrier with a great potential for future usage in cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell

Firouzi Amandi,

Bahmanyar,

Dadashpour

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Furthermore, Anu et al synthesized selenium nanoparticles (SeNPs) as green biogenesis NPs from Cassia auriculata and shown their effectiveness against leukemia cancer cells in vitro, as well as greater solubility and decreased toxicity on normal cells [ 91 ]. Niosomal formulations to encapsulate ifosfamide, alkylating anticancer drug, was developed to control its release and alleviate its toxicity [ 92 ]. Nanocarriers for efficient delivery of anti-leukemia drugs are summarized in Table 2 .…”

Section: Nanotechnology Approachesmentioning

confidence: 99%

Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials

Salama,

Aborehab,

El Mahdy

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Leukemia is a group of malignant disorders which affect the blood and blood-forming tissues in the bone marrow, lymphatic system, and spleen. Many types of leukemia exist; thus, their diagnosis and treatment are somewhat complicated. The use of conventional strategies for treatment such as chemotherapy and radiotherapy may develop many side effects and toxicity. Hence, modern research is concerned with the development of specific nano-formulations for targeted delivery of anti-leukemic drugs avoiding toxic effects on normal cells. Nanostructures can be applied not only in treatment but also in diagnosis. In this article, types of leukemia, its causes, diagnosis as well as conventional treatment of leukemia shall be reviewed. Then, the use of nanoparticles in diagnosis of leukemia and synthesis of nanocarriers for efficient delivery of anti-leukemia drugs being investigated in in vivo and clinical studies. Therefore, it may contribute to the discovery of novel and emerging nanoparticles for targeted treatment of leukemia with less side effects and toxicities.

show abstract

“…Niosomes are slightly different from liposomes as the bilayers are formed by non-ionic surfactants. The oxazaphosphorine family of alkylating drugs, Ifosfamide (IFO), when loaded with niosomes, showed potent activity with IC 50 of < 0.2 µg/ml against neuroblastoma SH-SY5Y cells [ 29 ] along with improved biochemical parameters against rat model of cancer with intravenous delivery of 0.2 mg/Kg of body weight. For liposomes, the stimuli-responsive drug delivery, where the stimuli can be pH-, redox-, enzyme-, light-, thermo-, and magneto-sensitive, is another advantage.…”

Section: Liposomementioning

confidence: 99%

An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success

Kumbhar,

Kumar,

Lasure

et al. 2023

Discover Nano

View full text Add to dashboard Cite

The recent development of nanotechnology-based formulations improved the diagnostics and therapies for various diseases including cancer where lack of specificity, high cytotoxicity with various side effects, poor biocompatibility, and increasing cases of multi-drug resistance are the major limitations of existing chemotherapy. Nanoparticle-based drug delivery enhances the stability and bioavailability of many drugs, thereby increasing tissue penetration and targeted delivery with improved efficacy against the tumour cells. Easy surface functionalization and encapsulation properties allow various antigens and tumour cell lysates to be delivered in the form of nanovaccines with improved immune response. The nanoparticles (NPs) due to their smaller size and associated optical, physical, and mechanical properties have evolved as biosensors with high sensitivity and specificity for the detection of various markers including nucleic acids, protein/antigens, small metabolites, etc. This review gives, initially, a concise update on drug delivery using different nanoscale platforms like liposomes, dendrimers, polymeric & various metallic NPs, hydrogels, microneedles, nanofibres, nanoemulsions, etc. Drug delivery with recent technologies like quantum dots (QDs), carbon nanotubes (CNTs), protein, and upconverting NPs was updated, thereafter. We also summarized the recent progress in vaccination strategy, immunotherapy involving immune checkpoint inhibitors, and biomarker detection for various cancers based on nanoplatforms. At last, we gave a detailed picture of the current nanomedicines in clinical trials and their possible success along with the existing approved ones. In short, this review provides an updated complete landscape of applications of wide NP-based drug delivery, vaccinations, immunotherapy, biomarker detection & imaging for various cancers with a predicted future of nanomedicines that are in clinical trials. Graphical abstract

show abstract

Development of a new vesicular formulation for delivery of Ifosfamide: Evidence from in vitro, in vivo, and in silico experiments

Cited by 11 publications

References 72 publications

Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell

Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell

Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials

An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success

Contact Info

Product

Resources

About